Three Years After CARMENA: What Have We Learned?
- PMID: 34325948
- DOI: 10.1016/j.eururo.2021.07.007
Three Years After CARMENA: What Have We Learned?
Abstract
Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.
Keywords: Cytoreductive nephrectomy; Renal cell carcinoma.
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment on
-
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Eur Urol. 2021 Oct;80(4):417-424. doi: 10.1016/j.eururo.2021.06.009. Epub 2021 Jun 27. Eur Urol. 2021. PMID: 34187771
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
